Nonoperating Income (Expense) of Dianthus Therapeutics, Inc. /DE/ from 31 Dec 2016 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Dianthus Therapeutics, Inc. /DE/ quarterly and annual Nonoperating Income (Expense) in USD history and change rate from 31 Dec 2016 to 31 Dec 2025.
  • Dianthus Therapeutics, Inc. /DE/ Nonoperating Income (Expense) for the quarter ending 31 Dec 2025 was $5,109,000, a 47% increase year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ Nonoperating Income (Expense) for the twelve months ending 31 Dec 2025 was $15,596,000, a 7.7% decline year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ annual Nonoperating Income (Expense) for 2025 was $15,596,000, a 7.7% decline from 2024.
  • Dianthus Therapeutics, Inc. /DE/ annual Nonoperating Income (Expense) for 2024 was $16,895,000, a 266% increase from 2023.
  • Dianthus Therapeutics, Inc. /DE/ annual Nonoperating Income (Expense) for 2023 was $4,619,000, a 276% increase from 2022.
Source SEC data
View on sec.gov
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Change (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Change (%)

Dianthus Therapeutics, Inc. /DE/ Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $15,596,000 $5,109,000 +$1,633,000 +47% 01 Oct 2025 31 Dec 2025 10-K 09 Mar 2026 2025 FY
Q3 2025 $13,963,000 $3,523,000 -$1,203,000 -25% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $15,166,000 $3,298,000 -$1,299,000 -28% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $16,465,000 $3,666,000 -$430,000 -10% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $16,895,000 $3,476,000 +$1,083,000 +45% 01 Oct 2024 31 Dec 2024 10-K 09 Mar 2026 2025 FY
Q3 2024 $15,812,000 $4,726,000 +$3,730,000 +374% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $12,082,000 $4,597,000 +$3,961,000 +623% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $8,121,000 $4,096,000 +$3,502,000 +590% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $4,619,000 $2,393,000 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
Q3 2023 $996,000 +$526,000 +112% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $636,000 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $594,000 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q3 2022 $470,000 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3

Dianthus Therapeutics, Inc. /DE/ Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $15,596,000 -$1,299,000 -7.7% 01 Jan 2025 31 Dec 2025 10-K 09 Mar 2026 2025 FY
2024 $16,895,000 +$12,276,000 +266% 01 Jan 2024 31 Dec 2024 10-K 09 Mar 2026 2025 FY
2023 $4,619,000 +$3,390,000 +276% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
2022 $1,229,000 +$1,252,000 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $23,000 01 Jan 2021 31 Dec 2021 8-K 21 Dec 2023
2018 $2,448,000 +$2,212,000 +937% 01 Jan 2018 31 Dec 2018 10-K 19 Mar 2019 2018 FY
2017 $236,000 +$399,000 01 Jan 2017 31 Dec 2017 10-K 19 Mar 2019 2018 FY
2016 $163,000 01 Jan 2016 31 Dec 2016 10-K 19 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.